4-(4-Chlorobenzyl)-3,4-dihydro-2-(2-hydroxyethyl)-3-oxo-2H-1,4-benzoxazine | 191096-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 4-(4-Chlorobenzyl)-3,4-dihydro-2-(2-hydroxyethyl)-3-oxo-2H-1,4-benzoxazine
• 英文别名: 4-[(4-Chlorophenyl)methyl]-2-(2-hydroxyethyl)-1,4-benzoxazin-3-one
• CAS: 191096-66-9
• 化学式: C₁₇H₁₆ClNO₃
• 分子量: 317.772
• InChiKey: NCYICEGXJGPPIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-Chlorobenzyl)-3,4-dihydro-2-(2-hydroxyethyl)-3-oxo-2H-1,4-benzoxazine 在 sodium hydroxide 、 三丁基膦 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 甲醇 、 苯 为溶剂， 生成 (3-{2-[4-(4-Chloro-benzyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]-ethoxy}-phenyl)-acetic acid
  参考文献：
  名称：

  Benzoxazinones as PPARγ agonists. part 1: SAR of three aromatic regions

  摘要：

  A series of benzoxazinones was synthesized as PPARgamma agonists. The compounds were obtained in seven steps, and SAR was developed by variations to the core shown below. The compounds were tested as functional agonists in the induction of the aP2 gene in preadipocytes, and the most potent compound in the series has an EC50=0.51 muM. The potency was further confirmed through a PPAR-Ga14 construct. Efficacy has been demonstrated in the db/db mouse model of hyperglycemia. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00401-3
• 作为产物：
  描述：

  3,4-二氢-2-(2-羟乙基)-3-氧代-2H-1,4-苯并恶嗪 在 咪唑 、 甲烷磺酸 、 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(4-Chlorobenzyl)-3,4-dihydro-2-(2-hydroxyethyl)-3-oxo-2H-1,4-benzoxazine
  参考文献：
  名称：

  Benzoxazinones as PPARγ agonists. part 1: SAR of three aromatic regions

  摘要：

  A series of benzoxazinones was synthesized as PPARgamma agonists. The compounds were obtained in seven steps, and SAR was developed by variations to the core shown below. The compounds were tested as functional agonists in the induction of the aP2 gene in preadipocytes, and the most potent compound in the series has an EC50=0.51 muM. The potency was further confirmed through a PPAR-Ga14 construct. Efficacy has been demonstrated in the db/db mouse model of hyperglycemia. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00401-3

文献信息

• Benzoxazine antimicrobial agents
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05696117A1

  公开（公告）日：1997-12-09

  The invention relates to benzoxazine and pyrido-oxazine antibacterial compounds of the general formula: ##STR1## wherein the moiety Q is a fused phenyl or fused pyridyl moiety as herein described, pharmaceutical compositions containing the compounds, methods for their production and their use in treating bacterial infections.

  该发明涉及一般式为：##STR1##的苯并噁嗪和吡啶噁嗪抗菌化合物，其中基团Q是如本文所述的融合苯或融合吡啶基团，含有这些化合物的药物组合物，其生产方法以及在治疗细菌感染中的应用。
• [EN] BENZOXAZINE ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS A BASE DE BENZOXAZINE
  申请人：ORTHO PHARMACEUTICAL CORPORATION

  公开号：WO1997017333A1

  公开（公告）日：1997-05-15

  (EN) The invention relates to benzoxazine and pyrido-oxazine antibacterial compounds of general formula (1), wherein the moiety Q is a fused phenyl or fused pyridyl moiety as herein described, pharmaceutical compositions containing the compounds, methods for their production and their use in treating bacterial infections.(FR) L'invention porte sur des composés antimicrobiens de benzoxazine et de pyrido-oxazyne de formule générale (1), dans laquelle la fraction Q est une fraction phényle condensée ou pyridyle condensée telle que spécifiée dans la description, des compositions pharmaceutiques contenant ces composés, leurs procédés de fabrication et leur utilisation dans le traitement des infections bactériennes.

  该发明涉及通式（1）的苯并噁唑和吡啶并噁唑抗菌化合物，其中基团Q是如本说明中所述的融合苯基或融合吡啶基团，以及含有这些化合物的制药组合物、其制备方法和在治疗细菌感染中的使用。
• BENZOXAZINE ANTIMICROBIAL AGENTS
  申请人：ORTHO PHARMACEUTICAL CORPORATION

  公开号：EP0869949A1

  公开（公告）日：1998-10-14
• US5696117A
  申请人：——

  公开号：US5696117A

  公开（公告）日：1997-12-09
• US5854242A
  申请人：——

  公开号：US5854242A

  公开（公告）日：1998-12-29